Revolution Medicines and the RAS Resistance Problem: Nicholas Hornstein Sees a Different Playbook
The phrase revolution medicines matters here because the story is not only about another RAS therapy, but about a company trying to confront resistance before a drug is even fully in the world. That is the central shift highlighted by Nicholas Hornstein, Assistant Professor at Northwell Health, in a post shared on LinkedIn.
Verified fact: Hornstein said drug development is usually linear: build the drug, use the drug, watch resistance appear, then respond. Informed analysis: He framed Revolution Medicines as doing something different, building around resistance in advance. His comment centered on RM-055, which he described as a unique concept disclosed at AACR26.
What is the central question behind revolution medicines?
The question is not whether resistance exists in RAS therapy. The question is whether developers should wait for it to emerge or design with it in mind from the start. Hornstein’s comments place revolution medicines inside that debate, not as a conventional follow-up strategy but as an example of planning for the next barrier before the first one is fully cleared.
Verified fact: Hornstein said that before DaraxONRASib is even fully in the world, Revolution Medicines is already building around resistance. Informed analysis: That suggests the company is treating resistance not as an afterthought, but as part of the drug’s expected life cycle. In a field where many programs compete on similar mechanisms, that distinction may matter as much as the drug itself.
What exactly did Nicholas Hornstein highlight about RM-055?
Hornstein singled out RM-055 as the notable element in the company’s approach. He called it a unique concept and linked it directly to the idea of anticipating resistance rather than reacting to it. The key point is not a broad promise of success; it is the strategic logic behind the development program.
Verified fact: The post named AACR26 as the setting where RM-055 was disclosed. Verified fact: Hornstein contrasted this with what he called the usual sequence in drug development. Informed analysis: The implied value of RM-055 is that it may represent a structural response to a known weakness in RAS therapy development. If resistance is expected, then designing around it from the beginning could reduce the time lost between first success and failure.
Why does Hornstein think this approach stands out in RAS therapy?
Hornstein’s broader point was not limited to one company. He described the current landscape as crowded, even overwhelming, with RAS therapies coming forward in large numbers. He said he had put together recent data to help make sense of the field, including KRAS inhibitor data from AACR2026 and prior work.
Verified fact: His compiled comparison covered G12C, G12D, and Pan-RAS programs, and he noted G12C OFF-state and RAS(ON) selective programs as part of the landscape. He also said the table included 18 G12C entries and G12D and Pan-RAS programs. Verified fact: He also said the list was not exhaustive and that some therapies, including Avutometinib, were not on it.
Informed analysis: Taken together, that picture suggests a field where differentiation is becoming harder. When many programs crowd the same space, a proactive resistance strategy may be more persuasive than incremental claims of novelty. That is where revolution medicines becomes a useful case study: not just in making a drug, but in deciding what happens after the first response.
Who benefits from a resistance-first strategy?
The immediate beneficiary appears to be the development program itself, because planning for resistance early may reduce strategic blind spots. Patients may also benefit if such design shortens the path from initial response to longer-lasting control. But Hornstein did not claim a clinical outcome in this post; he described a development philosophy.
Verified fact: Hornstein said this is “how we cure cancer, not more me-toos, ” a line that signals a preference for structural innovation over repetition. Informed analysis: That criticism suggests the real competition is not simply among RAS drugs, but between different ideas of progress. One model waits for failure and patches it later. The other tries to anticipate failure before it arrives.
Verified fact: The only named institutional affiliations in the material are Nicholas Hornstein, Assistant Professor at Northwell Health, and Revolution Medicines. No clinical data, regulatory outcomes, or comparative efficacy results were provided in the context.
What should readers take from the latest RAS therapy discussion?
The latest signal is not a finished answer, but a direction. Hornstein’s posts show a field moving quickly enough that even experts need comparison tables to track it. Within that crowd, revolution medicines stands out because its strategy appears to start with resistance as a design constraint rather than a post-launch problem.
Accountability point: That approach deserves close scrutiny because it raises the standard for what a RAS therapy should be. It is no longer enough to show that a drug can work at the start. The harder test is whether the development strategy assumes the drug will face resistance and prepares for that reality from day one. If Revolution Medicines can show that this logic holds up, it may influence how the field thinks about RAS therapy development. For now, the clearest takeaway is that revolution medicines is being judged not only by the drug in hand, but by the plan built around the resistance that follows.
